SCHEMBL31247565

SCHEMBL31247565

[2H]c1nc(NC(C)=O)sc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ DYRK1A Q13627 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ FBP1 P09467 1/20 0.40
▸ CCNE1 P24864 6/20 0.39
▸ CDK2 P24941 6/20 0.39
▸ CDK1 P06493 2/20 0.39
▸ CDK4 P11802 2/20 0.39
▸ ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749806 0.81 SMN1; SMN2 (0.59) LMNAKDM4EABL1POLBNPC1
SCHEMBL2175131 0.68 RAB9A (0.60) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL9740903 0.67 SMN1; SMN2 (0.55) LMNAKDM4EABL1POLBDYRK1A
SCHEMBL5216438 0.67 CCNE1 (0.48) LMNADYRK1ACCNE1CDK2CDK1
SCHEMBL1350381 0.67 CCNE1 (0.48) LMNADYRK1ACCNE1CDK2CDK1
SCHEMBL966406 0.67 ALOX15 (0.53) LMNACCNE1CDK2CDK1CDK4
SCHEMBL13158536 0.67 CCNE1 (0.48) LMNASMN1; SMN2CYP3A4CCNE1CDK2
SCHEMBL1763394 0.67 CCNE1 (0.48) LMNADYRK1ACCNE1CDK2CDK1
SCHEMBL30620430 0.67 — —
SCHEMBL4522999 0.67 CCNE1 (0.59) LMNANPC1RAB9ASMN1; SMN2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors LEIDOS BIOMEDICAL RESEARCH INC. 2025-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors TDP1, TDP2, TOP1 LMNA 1497/4885KDM4E 1381/4885ABL1 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback